{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.955","value":"2.53"},{"groupId":"OG001","spread":"0.948","value":"1.34"},{"groupId":"OG002","spread":"2.955","value":"3.01"},{"groupId":"OG003","spread":"2.232","value":"2.71"},{"groupId":"OG004","spread":"2.067","value":"1.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"The rate of RBC transfusion was defined as the average number of RBC units per participant-month during the treatment period.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"MEAN","populationDescription":"Full Analysis Set-MDS. Only participants who were on treatment for at least 78 days were included in the analysis.","reportingStatus":"POSTED","timeFrame":"from Week 12 through Week 24","title":"Rate of Red Blood Cell (RBC) Transfusion From Week 12 Through Week 24","type":"SECONDARY","unitOfMeasure":"RBC units per participant-month"}